Abacus FCF Advisors’s Bio-Techne TECH Stock Holding History

Abacus FCF Advisors’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,172	Closed	-$885K	–	179
2022 Q1	$885K	Buy	+8,172	New	+$843K	0.3%	133

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $29.1B AUM 43.86% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Abacus FCF Advisors's TECH Position: Q2 2022 in Review

Abacus FCF Advisors sold out of Bio-Techne (TECH) in Q2 2022, closing a stake of 8,172 shares — an estimated $885K sold.

Abacus FCF Advisors first reported a position in TECH in Q1 2022 and held it in 1 quarter. The position peaked at $885K in Q1 2022. 550 funds tracked by Wall St. Rank hold TECH as of Q2 2022.

Abacus FCF Advisors reported no remaining Bio-Techne position as of Q2 2022 after selling out during the quarter.
Abacus FCF Advisors sold 8,172 Bio-Techne shares in Q2 2022, an estimated $885K.
Abacus FCF Advisors first reported a position in Bio-Techne in Q1 2022 and held it in 1 quarter.
Abacus FCF Advisors's Bio-Techne position peaked at $885K in Q1 2022.
550 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2022.

Based on Abacus FCF Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.